← Evidence map

ArticleClinical and molecular hepatology2026

Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on "Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis".

Yang-Hyun BaekPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2026

this papercites it

Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on "Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis". | Socratic